Records containing: Hidradenitis Suppurativa (HS)
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-21An Open-label, Multicenter Study Assessing Efficacy and Safety of Secukinumab up to One Year in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-04-16A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
-
CLINICAL_TRIALS study record update · 2026-04-08A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
-
CLINICAL_TRIALS study record update · 2026-04-06A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-04-03A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-03-25A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-03-23A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-24A Multi-Reader Multi-Case (MRMC) Study for Assessing the Impact of Legit.Health Plus on the Clinical Assessment of Generalized Pustular Psoriasis and Other Skin Conditions by Healthcare Professionals.
-
CLINICAL_TRIALS study record update · 2026-02-24A Multi-Reader Multi-Case (MRMC) Study Assessing the Impact of Legit.Health Plus on the Diagnostic Accuracy and Referral Decision-Making of Primary Care Physicians for Skin Lesions.
-
CLINICAL_TRIALS study record update · 2026-02-17Radiotherapy for Treatment of Recalcitrant Hidradenitis Suppurativa (RADIANT-SUPPoRT)
-
CLINICAL_TRIALS study record update · 2026-02-12A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-11An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-10A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-05Role of Mucosal Associated Invariant T Cells in Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-03A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-02-02Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)
-
CLINICAL_TRIALS study record update · 2026-01-09A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-01-07Real-World Study on the Burden of Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2026-01-05Outcomes With Pelashield™ PainGuard™ Compared to Restrata® in Standard Two-Stage Excision and Closure for Hidradenitis Suppurativa: A Prospective Cohort With Retrospective Comparator
-
CLINICAL_TRIALS study record update · 2025-12-30Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA
-
CLINICAL_TRIALS study record update · 2025-12-18Managed Access Programs for AIN457, Secukinumab
-
CLINICAL_TRIALS study record update · 2025-12-12Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study
-
CLINICAL_TRIALS study record update · 2025-12-11The Investigation of TAAR1 and JAK/STAT Pathway Gene Expression and Protein Levels in Inflamed Skin Tissue Samples From Patients With Hidradenitis Suppurativa
-
CLINICAL_TRIALS study record update · 2025-12-03Comparison of the Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS: A Prospective Exploratory Trial
-
CLINICAL_TRIALS study record update · 2025-11-24A Phase II, Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SCT650C in Adult Participants With Moderate to Severe Hidradenitis Suppurativa